Illumina Inc (ILMN): Karin Eastham , director of Illumina Inc sold 5,000 shares on Jun 1, 2016. The Insider selling transaction was reported by the company on Jun 3, 2016 to the Securities and Exchange Commission. The shares were sold at $145.01 per share for a total value of $726,750.31 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 26, 2016, Christian O Henry (EVP & Chief Commercial Officer) sold 2,141 shares at $144.86 per share price.On May 13, 2016, A Blaine Bowman (director) sold 5,000 shares at $137.63 per share price.Also, On Apr 20, 2016, Paul L Bianchi (Sr. VP, Human Resources) sold 1,884 shares at $175.00 per share price.On Apr 14, 2016, Jay T Flatley (Chief Executive Officer) sold 20,000 shares at $170.14 per share price.
Shares of Illumina (ILMN) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -1.56 points or -1.06% at $145.54 with 6,85,370 shares getting traded. Post opening the session at $146.21, the shares hit an intraday low of $143.32 and an intraday high of $147 and the price vacillated in this range throughout the day. The company has a market cap of $21,423 M and the number of outstanding shares has been calculated to be 14,72,00,000 shares. The 52-week high of Illumina is $242.37 and the 52-week low is $127.1.
Company has been under the radar of several Street Analysts.Illumina is Reiterated by Mizuho to Neutral while Lowering the Price Target of the company shares to $ 138 from a previous price target of $150 . The Rating was issued on May 4, 2016.Illumina is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 160 from a previous price target of $215 . The Rating was issued on May 4, 2016.Illumina is Reiterated by Canaccord Genuity to Hold while Lowering the Price Target of the company shares to $ 140 from a previous price target of $160 . The Rating was issued on May 4, 2016.Illumina is Reiterated by Morgan Stanley to Overweight while Lowering the Price Target of the company shares to $ 130 from a previous price target of $140 . The Rating was issued on May 3, 2016.Illumina is Reiterated by UBS to Buy while Lowering the Price Target of the company shares to $ 180 from a previous price target of $210 . The Rating was issued on May 3, 2016.
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.